Eupraxia Pharmaceuticals【EPRX】銘柄情報

Eupraxia Pharmaceuticals Inc (EPRX) 銘柄情報

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

プレミアム

通貨

5.95

( -7.75% )

買値

5.94

売値

8.06

出来高

356,567

5.93 日の範囲 6.48

3.85 52 週間の範囲 9.32

時価総額

388.695M

前日終値

6.45

始値

6.48

時刻

6.2

最終取引時間

財務取引量

US$ 2,195,462

VWAP

6.1572

平均取引量 (3 か月)

US$ 64,271

発行済株式数

65,326,947

配当利回り

PER

-7.11

1 株当たり利益 (EPS)

-1.04

歳入

純利益

-44.47M

Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. The company’s produ... Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. The company’s product portfolio includes EP-104IAR, which is in Phase III clinical trial for the treatment of knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the treatment of gastrointestinal tract, such as eosinophilic esophagitis. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada. 詳細を表示

セクター

Healthcare

業界

Biotechnology & Life Sciences

ウェブサイト

www.eupraxiapharma.com

本社

Victoria, Canada

設立

2026

Eupraxia Pharmaceuticals Inc is listed in the Healthcare sector of the ナスダック市場 with ticker EPRX. The last closing price for Eupraxia Pharmaceuticals was US$6.45. Over the last year, Eupraxia Pharmaceuticals shares have traded in a share price range of US$ 3.85 to US$ 9.32.

Eupraxia Pharmaceuticals currently has 65,326,947 shares in issue. The market capitalisation of Eupraxia Pharmaceuticals is US$388.70 million. Eupraxia Pharmaceuticals has a price to earnings ratio (PE ratio) of -7.11.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	-1.43	-19.3766937669	7.38	7.51	5.965	278008	6.63184974	CS
4	-1.53	-20.4545454545	7.48	7.83	5.965	257286	6.89321953	CS
12	-1.51	-20.2412868633	7.46	8.13	5.965	213585	7.1297918	CS
26	0.01	0.16835016835	5.94	9.32	5.8726	208362	7.60213113	CS
52	2.0587	52.9051987768	3.8913	9.32	3.85	140404	7.14324127	CS
156	2.4	67.6056338028	3.55	9.32	2.2	73181	6.70245114	CS
260	2.4	67.6056338028	3.55	9.32	2.2	73181	6.70245114	CS